Navigation Links
ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20)
Date:12/6/2011

subcutaneous dispersion and absorption of these drugs. Molecules as large as 200 nanometers may pass freely through the extracellular matrix, which recovers its normal density within approximately 24 hours, leading to a drug delivery platform which does not permanently alter the architecture of the skin. The principal focus of Halozyme's Enhanze technology platform is the use of rHuPH20 to facilitate subcutaneous administration for large molecule biological therapeutics, some of which currently require intravenous administration.

About Hereditary Angioedema (HAE)

HAE is a rare, severely debilitating, life-threatening genetic disorder caused by a deficiency of C1 inhibitor, a human plasma protein. This condition is the result of a defect in the gene controlling the synthesis of C1 inhibitor. C1 inhibitor maintains the natural regulation of the contact, complement, and fibrinolytic systems, that when left unregulated, can initiate or perpetuate an attack by consuming the already low levels of endogenous C1 inhibitor in HAE patients. Patients with C1 inhibitor deficiency experience recurrent, unpredictable, debilitating, and potentially life threatening attacks of inflammation affecting the larynx, abdomen, face, extremities and urogenital tract. Patients with HAE experience approximately 20 to 100 days of incapacitation per year. There are estimated to be at least 6,500 people with HAE in the United States and at least 10,000 people in the European Union.

For more information on HAE, visit the HAEi's (International Patient Organization for C1 Inhibitor Deficiencies) website at www.haei.org and the U.S. HAE Association's website at: www.haea.org.

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet med
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. ViroPharma to Participate in Two November Healthcare Investor Conferences
2. ViroPharma to Acquire DuoCort Pharma AB, Adding Important European Orphan Drug to Commercial Pipeline
3. ViroPharma Incorporated Reports Third Quarter 2011 Financial Results
4. ViroPharma to Release 2011 Third Quarter Financial Results on October 27, 2011
5. ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreichs Ataxia
6. ViroPharma Announces Additional Securities Repurchase Program
7. ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
8. ViroPharmas Buccolam® (Midazolam, Oromucosal Solution) Granted European Marketing Authorization for Treatment of Acute Seizures
9. ViroPharma to Participate in the Stifel Nicolaus 2011 Healthcare Conference
10. ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union
11. ViroPharmas Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... April 24, 2015  Lannett Company, Inc. (NYSE: ... increased its five-year revolving credit facility to $120 million ... feature that will allow the company to increase borrowings ... million, subject to securing additional commitments from existing lenders ... credit facility remains December 18, 2018.   ...
(Date:4/24/2015)... Spain , April 24, 2015  Elekta has ... Monaco® treatment planning system , enabling European clinics ... supports major treatment techniques including advanced 3D planning, IMRT, ... system. Monaco ... as well improved workflow efficiency. Advancements in 3D planning ...
(Date:4/23/2015)...  Edwards Lifesciences Corporation (NYSE: EW ), the ... hemodynamic monitoring, today reported net income for the quarter ... diluted share.  Net income for the same period a ... share, and non-GAAP net income was $82.1 million, or ... the quarter ended March 31, 2015 increased 13.0 percent to ...
Breaking Medicine Technology:Lannett Expands Revolving Credit Facility To $120 Million 2Elekta CE marks for Monaco v5.10 treatment planning system 2Edwards Lifesciences Reports First Quarter Results 2Edwards Lifesciences Reports First Quarter Results 3Edwards Lifesciences Reports First Quarter Results 4Edwards Lifesciences Reports First Quarter Results 5Edwards Lifesciences Reports First Quarter Results 6Edwards Lifesciences Reports First Quarter Results 7Edwards Lifesciences Reports First Quarter Results 8Edwards Lifesciences Reports First Quarter Results 9Edwards Lifesciences Reports First Quarter Results 10Edwards Lifesciences Reports First Quarter Results 11Edwards Lifesciences Reports First Quarter Results 12Edwards Lifesciences Reports First Quarter Results 13Edwards Lifesciences Reports First Quarter Results 14Edwards Lifesciences Reports First Quarter Results 15Edwards Lifesciences Reports First Quarter Results 16
... 2 Results from studies related ... ) lead developmental product candidate, fidaxomicin, ... Annual Interscience Conference on Antimicrobial Agents and Chemotherapy ... and Exhibition Center in Boston on September 12-15, ...
... Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins... -- DALLAS, Texas, September 2, 2010 ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need ...
Cached Medicine Technology:Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting 2Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting 3Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 2Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 3Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 4Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 5Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 6Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 7Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 8
(Date:4/25/2015)... Caicos Islands, BWI (PRWEB) April 25, 2015 ... (PLS) has celebrated three months of successfully welcoming visitors ... January 5, 2015. , As part of a ... of Providenciales airport was completely redesigned to speed up ... up the process of getting out of the airport ...
(Date:4/25/2015)... On Friday, April 17, Interstate Batteries ... Best Implementation Award. This award is given to ... of RFID technology to improve its manufacturing, supply chain ... best demonstrates how RFID is delivering real value to ... Live! 2015 in San Diego, the RFID industries annual ...
(Date:4/24/2015)... As the nation recognizes the Month ... of these young men and women, the “Alaska – ... their Families” presents a special training session on Adverse ... a better understanding of the effect of childhood trauma ... – civilian and military – who provide services and ...
(Date:4/24/2015)... The 1975 have had an intense past two ... theaters, festivals and TV performances. Now that they’ve settled back ... Dirty Hit Records, to provide clean drinking water to those ... Cadence & Cause website, this four-piece has graciously donated ... signed photo card. Entries from this sweepstakes will ...
(Date:4/24/2015)... 2015 Anchor Health Administrators (Anchor), specialists ... today announced their exclusive agreement with LTC Solutions for ... Insurance distribution partner. , Anchor has more than 18 ... benefits for associations, and is currently the designated advocate ... Term Care Insurance member benefit. , “I am very ...
Breaking Medicine News(10 mins):Health News:The Tuscany on Grace Bay Celebrates Providenciales Airport Expansion With Summer Specials to Travelers! 2Health News:Seeonic’s Industry Leading Technology Powers Interstate Batteries to Winning Award 2Health News:Coalition Presents Resiliency Training to Raise Awareness during Month of the Military Child (#MOTMC2015) 2Health News:Internationally Recognized British Indie Rock Outfit The 1975 Partner with Cadence & Cause to Provide Clean Drinking Water to Those in Need 2
... In response to ... In Health (PIH) Stand with Haiti initiative. Buildium started the campaign with a $1,000 donation, ... ... ongoing needs in Haiti, Buildium today announced a fundraising campaign to benefit the Partners In ...
... , ... ... ... ...
... , ... ... , ... , , ...
... deal with physical pain, researchers say , THURSDAY, Feb. ... back pain may find relief through cognitive behavioral therapy, ... beliefs. , Chronic lower back pain is one of ... the British researchers report. And, it can be expensive ...
... , ... ... , , , ... ...
... drugs intended to halt growth of brain cancer stem cells ... conclude that blocking these cells may be somewhat effective, but ... the job done. One focus of attack is a ... shown is important for cancer stem cell growth. A new ...
Cached Medicine News:Health News:Buildium Announces Fundraising Campaign to Benefit Haiti Relief Efforts 2Health News:DNC Chairman Tim Kaine Applauds President, Members of Congress on Today's Bipartisan Summit 2Health News:DNC Chairman Tim Kaine Applauds President, Members of Congress on Today's Bipartisan Summit 3Health News:Clinton Bush Haiti Fund Awards International Medical Corps $500,000 for Emergency Medical Care and Long-Term Rebuilding 2Health News:Clinton Bush Haiti Fund Awards International Medical Corps $500,000 for Emergency Medical Care and Long-Term Rebuilding 3Health News:Chronic Back Pain Soothed by Cognitive Behavioral Therapy 2Health News:Chronic Back Pain Soothed by Cognitive Behavioral Therapy 3Health News:NSBA Implores Congress to Act on Health Care Reform 2Health News:NSBA Implores Congress to Act on Health Care Reform 3Health News:Notch-blocking drugs kill brain cancer stem cells, yet multiple therapies may be needed 2
The BioPro Basal Thumb joint is manufactured from Cobalt Chrome and is used to replace the Trapeziometacarpal joint....
... Acutrak Fusion Screw is a ... combination of variable thread pitch ... and holding power. The Acutrak ... fusions of the IP and ...
The efficient choice for small joint replacement technology -- the Ascension Silicone MCP features a similar design to our PyroCarbon MCP and utilizes the same instrumentation for intra-operative fle...
A flexible intramedullary-stemmed, one-piece implant developed as an adjunct to resection arthroplasty to help restore function to hands disabled by rheumatoid, degenerative or post-traumatic arthrit...
Medicine Products: